Table S4 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Table S2 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Figure S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Figure S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0
Table S4 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid TumorsMark W. Kieran, James A. Whitlock, Birgit Geoerger et al.|Unknown|2023Cited by 0